FCGR2B and systemic lupus erythematosus: The immunosuppressive version of anti-CD19 antibody (XmAb5871; Xencor) binds inhibitory FcγRIIb with ~430-fold enhanced affinity and efficiently depletes CD19+ B-cells in systemic lupus erythematosus (SLE) patients (90, 94).